Jia-Kang Wang1, Chung-May Yang2, Chang-Ping Lin3, Yin-Dong Shan2, Andy Y Lo1, Hwei-Fang Tien4. 1. Department of Ophthalmology, Far Eastern Memorial Hospital, Taipei, Taiwan. 2. Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan. 3. Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan. cpilin@ms7.hinet.net. 4. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Abstract
BACKGROUND: To demonstrate the efficacy of intravitreal methotrexate for treating intraocular lymphoma. CASE: A 55-year-old immunocompetent Asian man was diagnosed with intraocular lymphoma. OBSERVATIONS: The patient was initially managed by intravenous administration of high-dose methotrexate. Because vitreous cells persisted after systemic chemotherapy, methotrexate was given intravitreally thereafter. There was only self-limited corneal epitheliopathy without major complications following intraocular injections. Ocular remission was sustained during a 21-month follow-up. CONCLUSION: Intravitreal methotrexate is an effective, repeatable, and safe treatment for intraocular lymphoma. Copyright Japanese Ophthalmological Society 2006.
BACKGROUND: To demonstrate the efficacy of intravitreal methotrexate for treating intraocular lymphoma. CASE: A 55-year-old immunocompetent Asian man was diagnosed with intraocular lymphoma. OBSERVATIONS: The patient was initially managed by intravenous administration of high-dose methotrexate. Because vitreous cells persisted after systemic chemotherapy, methotrexate was given intravitreally thereafter. There was only self-limited corneal epitheliopathy without major complications following intraocular injections. Ocular remission was sustained during a 21-month follow-up. CONCLUSION: Intravitreal methotrexate is an effective, repeatable, and safe treatment for intraocular lymphoma. Copyright Japanese Ophthalmological Society 2006.
Authors: Justine R Smith; James T Rosenbaum; David J Wilson; Nancy D Doolittle; Tali Siegal; Edward A Neuwelt; Jacob Pe'er Journal: Ophthalmology Date: 2002-09 Impact factor: 12.079